Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Sichuan University

Medshine Discovery Inc.

Hubei Bio-pharmaceutical Industrial Technological Institute Inc.

Changzhou Yinsheng Pharmaceutical Co., Ltd.

Jumbo Drug Bank Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

Humanwell Healthcare Co., Ltd.

Chunli Shen

Chengde Wu

Shuhui Chen

Jian Li

Guoping Hu

Xin Tian

Shenglin Chen

Xiquan Zhang

Jiahu Wu

Ting Wang

Yong Liang Liu

Yong Liu

Lin Zhang

Yuquan Wei

Fei Liu

Yong Xu

Yi Zhang

Zhen Gong

Lu Huang

Xuehai Wang

Xiawei Wei

Ronghua Tu

Wei Zheng

Jie Shen

Hailiang Chen

Wenjie Sun

Ning Jiang

XiaWei Wei

Jing Yang

Wen Zhou

Zhongwen Yang

Yang Yue

Qiang Xiao

Hua Tian

Yanping Yu

Jing Tang

Luoting Yu

Xin Tao

Li'e Li

Nengyang Shi

Zhenyu He

Jing Yu

Quan Liu

Guanglong Sun

Huanyu Bian

Yuing Guo

Diliang Guo

Xuwen Zhang

The present application belongs to the field of medicine, and in particular relates to a crystal of a diarylthiohydantoin compound, a preparation method therefor, and use thereof in the preparation of medicaments for treating related diseases which are androgen-mediated.

Crystal of diarylthiohydantoin compound

Disclosed are a solid form and a crystal form of a compound represented by formula (I) used as a BRD4 inhibitor, a preparation method therefor, and an application thereof in the preparation of a medicine for treating BRD4-related diseases. (I).

BRD4 inhibitor compound in solid form and preparation method therefor and use thereof

The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

Diarylthiohydantoin compound as androgen receptor antagonist

The present application relates to the field of medicine. Specifically, disclosed are a compound of formula (I), a preparation method therefor, and a pharmaceutical composition comprising the compound.

Heterocyclic compound

Disclosed are a class of BTK kinase inhibitor compounds with a high activity and a high selectivity and the use thereof in the preparation of a drug for treating BTK target-related diseases. Specifically, disclosed are a compound shown as formula (I), and an isomer and a pharmaceutically acceptable salt thereof.

Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors

The present invention relates to a class of thienodiazepine derivatives and an application thereof in the preparation of a drug for the treatment of diseases associated with bromodomain and extra-terminal (BET) Bromodomain inhibitors. Specifically, the present invention relates to compounds represented by formulas (I) and (II), as well as pharmaceutically acceptable salts thereof. 

Thienodiazepine derivatives and application thereof

Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV). 

BTK inhibitor

A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

Hepatitis C virus inhibitors and uses thereof in preparation of drugs

Growing community of inventors

Shanghai, China

Chunli Shen